drug repositioning beyond the low-hanging fruits：（药物重新定位在低处的水果）.pdfVIP

Available online at Current Opinion in ScienceDirect Systems Biology Review Drug repositioning beyond the low-hanging fruits 1 1 1,2 Miquel Duran-Frigola , Lidia Mateo and Patrick Aloy Abstract To date, there are about 1,214 FDA-approved small Approved drug molecules have undergone safety and efficacy molecule drugs effectively targeting 733 proteins [2*]. examination, succeeding in a series of screens with typically To this, one can add drugs that are approved by other high attrition rates. Today, these privileged entities are well regulatory agencies, those in late clinical trials and characterized: the amount of data that has been collected for compounds that passed human safety tests but, for some drugs — from mechanisms of action to all sorts of molecular reason, were never commercialized. Because drugs can signatures — is far beyond that of the rest of compounds have more than one target, and targets may be hit by available to researchers. As biomedicine is going omics, and more than one drug [3], there are plenty of low-hanging with the advent of systems biology, drug molecules constitute a fruits. Several computational methods undertake this standard toolbox to probe and challenge disease models, task, searching for similarities between drugs in which are increasing in complexity and start to account for different therapeutic fields. Drugs with the same target patient variability. Here, we discuss why drug repo